Cerus (NASDAQ:CERS) & Neogen (NASDAQ:NEOG) Head to Head Contrast

Cerus (NASDAQ:CERS – Get Free Report) and Neogen (NASDAQ:NEOG – Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, valuation and profitability.

Profitability

This table compares Cerus and Neogen’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cerus -3.23% -10.44% -3.42%
Neogen -6.35% 3.29% 2.06%

Volatility & Risk

Cerus has a beta of 1.84, meaning that its stock price is 84% more volatile than the S&P 500. Comparatively, Neogen has a beta of 1.86, meaning that its stock price is 86% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Cerus and Neogen, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cerus 1 1 3 0 2.40
Neogen 1 1 3 0 2.40

Cerus currently has a consensus target price of $5.25, suggesting a potential upside of 183.02%. Neogen has a consensus target price of $12.67, suggesting a potential upside of 19.52%. Given Cerus’ higher probable upside, equities analysts clearly believe Cerus is more favorable than Neogen.

Institutional and Insider Ownership

78.4% of Cerus shares are owned by institutional investors. Comparatively, 96.7% of Neogen shares are owned by institutional investors. 5.3% of Cerus shares are owned by insiders. Comparatively, 0.5% of Neogen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Cerus and Neogen”s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cerus $206.13 million 1.82 -$15.63 million ($0.03) -61.83
Neogen $870.40 million 2.66 -$7.90 million ($0.25) -42.39

Neogen has higher revenue and earnings than Cerus. Cerus is trading at a lower price-to-earnings ratio than Neogen, indicating that it is currently the more affordable of the two stocks.

Summary

Neogen beats Cerus on 8 of the 12 factors compared between the two stocks.

About Cerus

(Get Free Report)

Cerus Corporation is a biomedical products company focused on improving the safety of blood components used for transfusions. Its primary offering is the INTERCEPT Blood System, which uses a pathogen-reduction process designed to inactivate a broad range of viruses, bacteria, parasites and white blood cells in donated blood components. INTERCEPT is used to process platelet and plasma components. Cerus also develops related processing devices and supplies for blood centers and transfusion services.

About Neogen

(Get Free Report)

Neogen Corporation develops and markets products and services focused on food and animal safety. Its offerings help food producers, processors, laboratories and livestock producers detect risks, support animal health and meet safety and quality requirements. Neogen’s food safety products include tests for foodborne pathogens, allergens, toxins and sanitation indicators, as well as related laboratory supplies and services. Its animal safety offerings include veterinary instruments, animal health products, biosecurity solutions and genetic testing services for livestock.

Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.